Helix Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Pharmaceuticals; anti-proliferative agents. Helix will pursue a three-pronged attack on fibrosis, blocking key enzymes responsible for cellular proliferation, formation of collagen and production of funtional tissue growth factor-b. The company initially plans to focus on fibrosis resulting from medical or surgical procedures.